Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

BelgiumBack to Belgium

Clinical trials in Genk – page 97

1 420 clinical trials in Genk, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Genk at a glance
1 420
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 420 trials in Genk

Open in trial search

Squamous cell carcinoma of skin

Not recruiting

Study of mRNA-4157 and Pembrolizumab for Patients with Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Mantle cell lymphoma

Not recruiting

Study of Zanubrutinib and Rituximab Compared to Bendamustine and Rituximab for Patients with Untreated Mantle Cell Lymphoma Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:BeOne Medicines AG

Cardiac operation

Not recruiting

Study of Vitamin C (Ascorbic Acid) in Patients Undergoing Open-Heart Surgery to Reduce Post-Surgery Inflammation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid
  • Sponsor:GCP-Service International West GmbH

Chronic lymphocytic leukaemia

Not recruiting

Study on Obinutuzumab and Venetoclax for Elderly Patients with Chronic Lymphocytic Leukemia Unfit for Standard Treatments

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Hypercholesterolaemia

Not recruiting

Study Comparing Inclisiran and Bempedoic Acid for Lowering LDL Cholesterol in Patients with Atherosclerotic Cardiovascular Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Novartis Pharma GmbH

Adenocarcinoma gastric+1

Not recruiting

Study of Pembrolizumab with Chemotherapy for Patients with Gastric or Gastroesophageal Junction Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Calcium Folinate
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer stage IV

Not recruiting

Study of Sotorasib Treatment for First-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Sotorasib
  • Sponsor:Amgen Inc.

Hidradenitis

Not recruiting

Study on Long-Term Use of Spesolimab for Patients with Hidradenitis Suppurativa Who Completed a Previous Spesolimab Study

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Paroxysmal nocturnal haemoglobinuria

Not recruiting

Study on Long-Term Safety and Tolerability of Iptacopan for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Small cell lung cancer extensive stage

Not recruiting

Study of BMS-986012, carboplatin, etoposide and nivolumab combination as first treatment for patients with extensive-stage small cell lung cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atigotatug
  • Sponsor:Bristol Myers Squibb International Corporation

Non-small cell lung cancer

Not recruiting

Study of Durvalumab with Radiation Therapy for Patients with Early Stage Non-Small Cell Lung Cancer and Osimertinib for Those with EGFR Mutation

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

B-cell small lymphocytic lymphoma

Not recruiting

Study Comparing Zanubrutinib with Bendamustine and Rituximab for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:BeOne Medicines AG

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Genk

What the registry says about research in the country

01 Respiratory Disease Trials

Extensive research focusing on respiratory syncytial virus (RSV) and influenza prevention in older adults. Studies evaluate innovative vaccine combinations and immune responses in participants over 60 years.

  • RSV and human metapneumovirus vaccines
  • High-dose Influenza vaccines
  • Vaccine co-administration studies

Multiple trials aim to enhance protection against respiratory infections in vulnerable populations.

02 Cardiovascular Research

Comprehensive studies addressing various aspects of heart disease and related conditions, including innovative treatments for hypertrophic cardiomyopathy and heart failure.

  • Acute Heart Failure treatments
  • Pulmonary Hypertension therapies
  • Cardiovascular disease prevention

Trials explore new therapeutic approaches for managing complex cardiac conditions.

03 Autoimmune Conditions

Clinical research examining treatments for various autoimmune disorders, including innovative therapies for rheumatoid arthritis and Sjögren's syndrome.

  • Psoriatic Arthritis treatments
  • Rheumatoid Arthritis therapies
  • Primary Sjögren's Disease interventions

Studies focus on improving treatment outcomes and quality of life for patients with autoimmune conditions.

Back to BelgiumAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.